PARP-1-IN-2

®

Cat. No.:	HY-147027
CAS No.:	684234-55-7
Molecular Formula:	$C_{22}H_{15}Cl_{2}N_{3}O_{2}$
Molecular Weight:	424.28
Target:	PARP; Caspase; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ν Q CI N H ∏ O

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (196.40 mM; Need ultrasonic)					
		Mass Solvent Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	2.3569 mL	11.7847 mL	23.5693 mL	
		5 mM	0.4714 mL	2.3569 mL	4.7139 mL	
		10 mM	0.2357 mL	1.1785 mL	2.3569 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.90 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution					

BIOLOGICAL ACTIV	ІТҮ ———				
Description	PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC ₅₀ of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis ^[1] .				
IC₅₀ & Target	PARP-1 149 ± 11.0 nM (IC ₅₀)	Caspase-3	Caspase-9		
In Vitro	PARP-1-IN-2 (compound 11g) (0-10 μM, 24-48 h) shows significantly potent anti-proliferative activity against A549 cells ^[1] . PARP-1-IN-2 (0-10 μM, 24 h) decreases the expression of pro-caspase-3 and phosphorylated AKT, increases the expression of caspase-3, caspase-9 protein and the cleaved PARP-1 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				



Cell Line:	A549, HFF cells ^[1]
Concentration:	0, 0.1, 1, 10 μΜ
Incubation Time:	24, 48 h
Result:	Showed significantly potent anti-proliferative activity against A549 cells, and didn't display any significant cytotoxicity on HFF cells.
Western Blot Analysis	
Cell Line:	A549 cells ^[1]
Concentration:	0, 0.1, 1, 10 μΜ
Incubation Time:	24 h
Result:	Reduced expression of pro-caspase-3 and phosphorylated AKT, significantly increased the expression of caspase-3 and caspase-9 protein, and enhanced expression of the cleaved PARP-1

REFERENCES

[1]. Almahli H, et al. Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer. Bioorg Chem. 2018 Apr;77:443-456.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA